%0 Journal Article %A Rodger Kempsford %A Amanda Oliver %A Lee Tombs %A Jo Bal %T The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening %D 2012 %J European Respiratory Journal %P P2090 %V 40 %N Suppl 56 %X Introduction: The novel corticosteroid FF and long-acting beta2 agonist VI combination (FF/VI) is being developed as a once-daily inhaled treatment for asthma and COPD.Objectives: To investigate the effect of time of day of dosing (AM or PM) on the efficacy of FF/VI (100/25mcg).Methods: Single centre, randomised, double-blind, placebo-controlled, three-way crossover study. Subjects with persistent asthma [N=26; 24–64 years] received FF/VI (AM or PM) or matching placebo (P) once daily for 14(±2) days. FEV1 (0–24h weighted mean and pre-treatment [AM and PM]) was determined after the Day 14 PM dose together with pre-treatment [AM and PM] PEF on Days 1–12.Results: FF/VI administered AM or PM produced clinically significant increases in weighted mean FEV1: the differences [95% CI] from P were 377mL [293, 462] and 422mL [337, 507], respectively; the difference between AM and PM dosing was –44mL [–125, 36]. Pre-treatment AM FEV1 differences [95% CI] from P were 403mL [272, 533] and 496mL [369, 624] after AM and PM dosing, respectively; the treatment difference was –94mL [–221, 34]. Pre-treatment PM FEV1 differences [95% CI] from P were 275mL [169, 380] and 309mL [205, 413] after AM and PM dosing, respectively; the treatment difference was –34mL [–138, 70]. FF/VI (AM or PM) produced rapid increases in PEF with the full effect apparent after the first dose and maintained throughout the 14 day treatment period.Conclusion: The efficacy of FF/VI (100/25mcg) was comparable when dosed in the morning or evening in subjects with persistent asthma.Funded by GSK (HZA114624; NCT01287065). %U https://erj.ersjournals.com/content/erj/40/Suppl_56/P2090.full.pdf